MarketCap
Facebook
X
TelegramQuartalsbericht 2022-Q3
hinzugefügt 08.11.2022
Albireo Pharma Betriebsaufwand 2011-2026 | ALBO
Betriebsaufwand Jährlich Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 163 M | 105 M | 70.7 M | 50.6 M | 24.6 M | 14 M | 19.8 M | 19.3 M | 20.6 M | 19.3 M | 23.2 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 163 M | 14 M | 48.1 M |
Betriebsaufwand Vierteljährlich Albireo Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 42.4 M | 35.5 M | 41.7 M | - | 29.2 M | 20.1 M | 31.1 M | - | 22 M | 16.5 M | 15.9 M | - | 12.9 M | 11.1 M | 11.8 M | - | 6.53 M | 6.61 M | 6.1 M | - | 3.47 M | 6.03 M | 2.75 M | 3.23 M | 16.3 M | 6.58 M | 4.53 M | 5.24 M | 15.6 M | 4.75 M | 5.24 M | 5.04 M | 16.2 M | 5.22 M | 5.04 M | 5.91 M | 13.6 M | 4.73 M | 5.91 M | 4.37 M | 18.6 M | 5.32 M | 4.37 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 42.4 M | 2.75 M | 12.6 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M |  USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
AbCellera Biologics
ABCL
|
292 M | $ 3.63 | - | $ 1.08 B |  Canada |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
ADMA Biologics
ADMA
|
101 M | $ 16.54 | - | $ 3.94 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Apellis Pharmaceuticals
APLS
|
948 M | $ 19.86 | - | $ 2.51 B | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.83 | - | $ 4.53 M | China |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 8.37 | - | $ 1.36 B | Britain |
 |
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
Cabaletta Bio
CABA
|
74.7 M | $ 3.43 | 5.54 % | $ 4.01 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
127 M | $ 76.53 | - | $ 1.48 B | USA |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | USA |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
44.9 M | - | - | $ 521 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
206 M | $ 24.69 | - | $ 3.02 B | USA |
 |
Citius Pharmaceuticals
CTXR
|
42 M | $ 0.82 | - | $ 5.52 M | USA |
 |
Axsome Therapeutics
AXSM
|
99.1 M | $ 164.08 | - | $ 8.16 B | USA |
 |
Champions Oncology
CSBR
|
12.5 M | $ 6.0 | - | $ 82 M | USA |
 |
BridgeBio Pharma
BBIO
|
304 M | $ 66.54 | - | $ 12.7 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Equillium
EQ
|
50.6 M | $ 1.75 | -1.13 % | $ 60.8 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
28.5 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | USA |
 |
Eton Pharmaceuticals
ETON
|
22.3 M | $ 17.53 | - | $ 450 M | USA |
 |
Evogene Ltd.
EVGN
|
28 M | $ 0.84 | - | $ 27.9 M |  Israel |
 |
Exelixis
EXEL
|
598 M | $ 41.69 | - | $ 11.3 B | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
22.4 M | - | -74.18 % | $ 955 K | USA |
 |
BioLineRx Ltd.
BLRX
|
28.1 M | $ 2.81 | - | $ 908 M | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
1.47 B | $ 60.43 | - | $ 11.6 B | USA |